Name:
Dr Sharon Smith
Organisation:
DevelRx Ltd
Year elected:
2024
Primary professional setting:
Consultancy
I am an Executive Director and co-founder of DevelRx Ltd, which offers consultancy services to the pharmaceutical, biotech and food supplement industry. I specialise in non-clinical drug abuse evaluation and the development of new treatments for drug abuse and dependence. I also work with our pharma clients in drug discovery and development for treatment of psychiatric and neurological disorders. I design and supervise non-clinical studies for evaluation of the abuse/dependence potential of novel CNS drugs and of treatments for substance use disorders. I prepare regulatory submissions of drug abuse potential and for safety and toxicity evaluation of food supplements (e.g. cannabidiol; CBD). I have contributed to the development and successful registration of more than 8 drugs including samidorphan and cannabidiol.Previously I worked for 16 years at a UK CRO from the time of its inception to growth into a global company. I was the most senior member of the Drug Abuse Evaluation and Consultancy Group below the Head of Department. I have also worked in the pharma and biotech industries and for 12 years in academia at Nottingham, Manchester, Bristol and Oxford Universities.